For neuroradiologists, the Signa Magnus 3T MRI system may offer enhanced visualization of the brain microstructure, microvasculature, and function.
Offering a combination of advanced gradient technology, deep-learning algorithms and short echo times, GE HealthCare is showcasing the new Signa Magnus 3T MRI at the International Society for Magnetic Resonance in Medicine (ISMRM) Annual Meeting in Singapore, Asia.
Featuring a gradient strength of 300 mT/m and slew rate of 750 T/m/s, the Signa Magnus is dedicated to head-only MRI imaging and reportedly provides enhanced imaging detail of the brain’s function, microstructure, and microvasculature, according to GE HealthCare.
Reportedly offering enhanced imaging detail of the brain’s function, microstructure, and microvasculature, the head-only 3T MRI system Signa Magnus provides higher b-value diffusion with short echo times, according to GE HealthCare, the manufacturer of the device. (Photo courtesy of GE HealthCare.)
In addition to deep-learning algorithms to bolster advanced imaging techniques, the company said another key attribute of the Signa Magnus MRI system is the capability to achieve higher b-value diffusion with short echo times.
"With Signa Magnus, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care.” said Kelly Londy, the chief executive officer of MR for GE HealthCare. “This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what's possible in MR imaging. The potential impact of Signa Magnus on patient outcomes and our understanding of the human brain is profound."
GE HealthCare noted that the Signa Magnus system is pending 510(k) clearance from the Food and Drug Administration (FDA).
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.